Mizolastine (BioDeep_00000858588)
代谢物信息卡片
化学式: C24H25FN6O (432.20737719999994)
中文名称: 咪唑司汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
InChI: InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
描述信息
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial[1][2][3].
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:31857
- KEGGdrug: D01117
- PubChem: 65906
- DrugBank: DB12523
- ChEMBL: CHEMBL94454
- CAS: 108612-45-9
- medchemexpress: HY-B0164
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ghada Ahmed El-Emam, Germeen N S Girgis, Mohammed Fawzy Hamed, Osama Abd El-Azeem Soliman, Abd El Gawad H Abd El Gawad. Formulation and Pathohistological Study of Mizolastine-Solid Lipid Nanoparticles-Loaded Ocular Hydrogels.
International journal of nanomedicine.
2021; 16(?):7775-7799. doi:
10.2147/ijn.s335482. [PMID: 34853513] - Siyu Yan, Wangqing Chen, Cong Peng, Wu Zhu, Mingliang Chen, Jianglin Zhang, Juan Su, Fangfang Li, Zhaoqian Liu, Wei Zhang, Qingling Li, Jie Li, Xiang Chen. C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level.
Experimental dermatology.
2019 03; 28(3):240-246. doi:
10.1111/exd.13874. [PMID: 30632650] - Shuibin Feng, Lei Nie, Peng Zou, Jinping Suo. Drug-loaded PLGA-mPEG microparticles as treatment for atopic dermatitis-like skin lesions in BALB/c mice model.
Journal of microencapsulation.
2015; 32(2):201-9. doi:
10.3109/02652048.2014.995727. [PMID: 25539424] - Wenhua Gao, Yunsheng Chen, Gaopan Chen, Jing Xi, Yaowen Chen, Jianying Yang, Ning Xu. Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Sep; 904(?):121-7. doi:
10.1016/j.jchromb.2012.07.032. [PMID: 22902104] - Zhong Hua, Hao Fei, Xiang Mingming. Evaluation and interference of serum and skin lesion levels of leukotrienes in patients with eczema.
Prostaglandins, leukotrienes, and essential fatty acids.
2006 Jul; 75(1):51-5. doi:
10.1016/j.plefa.2006.02.007. [PMID: 16757158] - M Molimard, B Diquet, M Strolin Benedetti. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Fundamental & clinical pharmacology.
2004 Aug; 18(4):399-411. doi:
10.1111/j.1472-8206.2004.00254.x. [PMID: 15312146] - Hong Li, Hongyu Zhang, Jia Yin, Ruiqi Wang, Quan Fang. [Clinical examination of mizolastine in the seasonal allergic rhinitis].
Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology.
2004 Aug; 18(8):479-81. doi:
NULL. [PMID: 15571316] - B Lebrun-Vignes, B Diquet, O Chosidow. Clinical pharmacokinetics of mizolastine.
Clinical pharmacokinetics.
2001; 40(7):501-7. doi:
10.2165/00003088-200140070-00002. [PMID: 11510627] - C Deschamps, C Dubruc, F Mentre, P Rosenzweig. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Clinical pharmacology and therapeutics.
2000 Dec; 68(6):647-57. doi:
10.1067/mcp.2000.112341. [PMID: 11180025] - M Taglialatela, A Pannaccione, P Castaldo, G Giorgio, L Annunziato. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine.
British journal of pharmacology.
2000 Nov; 131(6):1081-8. doi:
10.1038/sj.bjp.0703654. [PMID: 11082114] - S Oddera, F Cagnoni, P Dellacasa, G W Canonica. Effects of mizolastine in vitro on human immunocompetent and airway cells: evidence for safety and additional property.
International archives of allergy and immunology.
2000 Oct; 123(2):162-9. doi:
10.1159/000024436. [PMID: 11060489] - F Horak. Clinical advantages of dual activity in allergic rhinitis.
Allergy.
2000; 55 Suppl 64(?):34-9. doi:
10.1034/j.1398-9995.2000.00805.x. [PMID: 11291779] - J M Nicolas, R Whomsley, P Collart, J Roba. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines.
Chemico-biological interactions.
1999 Nov; 123(1):63-79. doi:
10.1016/s0009-2797(99)00131-3. [PMID: 10597902] - F E Simons. Mizolastine: antihistaminic activity from preclinical data to clinical evaluation.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
1999 Mar; 29 Suppl 1(?):3-8. doi:
NULL. [PMID: 10209699] - J Ring, K Brockow, M Ollert, R Engst. Antihistamines in urticaria.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
1999 Mar; 29 Suppl 1(?):31-7. doi:
10.1046/j.1365-2222.1999.00006.x. [PMID: 10209703] - F Mesnil, F Mentré, C Dubruc, J P Thénot, A Mallet. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.
Journal of pharmacokinetics and biopharmaceutics.
1998 Apr; 26(2):133-61. doi:
10.1023/a:1020505722924. [PMID: 9795879] - O Chosidow, C Dubruc, P Danjou, E Fuseau, E Espagne, G Bianchetti, J P Thenot, S Herson, P Rosenzweig, J Revuz. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
European journal of clinical pharmacology.
1996; 50(4):327-33. doi:
10.1007/s002280050117. [PMID: 8803528] - J L Pinquier, H Caplain, M J Cabanis, C Dubruc, A Stalla-Bourdillon, P Rosenzweig. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine.
Journal of clinical pharmacology.
1996 Jan; 36(1):72-8. doi:
10.1002/j.1552-4604.1996.tb04154.x. [PMID: 8932546] - A Patat, L F Gram, C Dubruc, S Brohier, M J Cabanis, P Rosenzweig. Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects.
International clinical psychopharmacology.
1994; 9(2):101-8. doi:
10.1097/00004850-199400920-00006. [PMID: 8056991] - V Ascalone, P Guinebault, A Rouchouse. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid-liquid extraction, solid-phase extraction and column-switching techniques in combination with high-performance liquid chromatography.
Journal of chromatography.
1993 Sep; 619(2):275-84. doi:
10.1016/0378-4347(93)80117-m. [PMID: 7903309]